NonExomics
NonExomics, Inc. is a genomics company pioneering the discovery of novel drug targets by mining the entire human genome, beyond the conventional 1-2% gene regions. Using a proprietary, patent-pending machine learning platform developed over eight years, it identifies and validates over 250,000 previously undiscovered proteins and nearly 3,000 novel targets linked to 1,365 human diseases. The company integrates genomics, transcriptomics, proteomics, and AI to reveal druggable noncanonical proteins, enabling new therapeutic and diagnostic opportunities for difficult-to-treat diseases such as cancer, neuropsychiatric disorders, and rare diseases. Founded by scientists from Harvard and Cambridge, NonExomics holds a first-mover advantage with a growing patent portfolio and has attracted investment from Illumina Accelerator. It collaborates with biotech, pharma, and academic partners to advance its targets toward clinical development.
NonExomics
NonExomics, Inc. is a genomics company pioneering the discovery of novel drug targets by mining the entire human genome, beyond the conventional 1-2% gene regions. Using a proprietary, patent-pending machine learning platform developed over eight years, it identifies and validates over 250,000 previously undiscovered proteins and nearly 3,000 novel targets linked to 1,365 human diseases. The company integrates genomics, transcriptomics, proteomics, and AI to reveal druggable noncanonical proteins, enabling new therapeutic and diagnostic opportunities for difficult-to-treat diseases such as cancer, neuropsychiatric disorders, and rare diseases. Founded by scientists from Harvard and Cambridge, NonExomics holds a first-mover advantage with a growing patent portfolio and has attracted investment from Illumina Accelerator. It collaborates with biotech, pharma, and academic partners to advance its targets toward clinical development.